Merck CEO: Cancer vaccine production timeline to shorten
Merck CEO Rob Davis expects the personalized cancer vaccine the company is developing with Moderna to become faster to manufacture over time, according to an Oct. 14 CNBC report. The current turnaround is about six weeks, from sequencing a patient’s tumor to delivering the vaccine to the hospital. The vaccine, intismeran autogene, is made individually […] The post Merck CEO: Cancer vaccine production timeline to shorten appeared first on Becker's Hospital Review | Healthcare New...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.